drugset / Trial / NCT07187856
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
Timeline
- Start
- 2026-01
- Primary completion
- 2026-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PG-102 | Monoclonal antibody | — | Subcutaneous |
| Comparator | Semaglutide | Peptide | 1 mg | Subcutaneous |